<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Janux Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/janux-therapeutics-inc</link>
<description>Latest news and press releases for Janux Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/janux-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683587e278dffbe2df0fe907.webp</url>
<title>Janux Therapeutics Inc</title>
<link>https://6ix.com/company/janux-therapeutics-inc</link>
</image>
<item>
<title>Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-discontinuation-of-janx008-clinical-development</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-discontinuation-of-janx008-clinical-development</guid>
<pubDate>Mon, 27 Apr 2026 20:01:00 GMT</pubDate>
<description>SAN DIEGO, April 27, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program.</description>
</item>
<item>
<title>Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-first-participant-dosed-in-phase-1-study-of-janx014</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-first-participant-dosed-in-phase-1-study-of-janx014</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>-JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development</description>
</item>
<item>
<title>Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-development-candidate-nomination-under-bristol-myers-squibb-collaboration-triggering-dollar35-million-milestone-payment</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-development-candidate-nomination-under-bristol-myers-squibb-collaboration-triggering-dollar35-million-milestone-payment</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel</description>
</item>
<item>
<title>Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic</description>
</item>
<item>
<title>Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-janx011</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-janx011</guid>
<pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel</description>
</item>
<item>
<title>Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-appoints-william-go-md-phd-chief-medical-officer-2026-01-26</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-appoints-william-go-md-phd-chief-medical-officer-2026-01-26</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based</description>
</item>
<item>
<title>Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-collaboration-and-exclusive-worldwide-license-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-collaboration-and-exclusive-worldwide-license-agreement</guid>
<pubDate>Thu, 22 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of</description>
</item>
<item>
<title>Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-provides-program-update-ongoing-phase-1-janx008-study-2025-12-23</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-provides-program-update-ongoing-phase-1-janx008-study-2025-12-23</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel</description>
</item>
<item>
<title>Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-announces-encouraging-efficacy-and-safety-profile-ongoing-phase-1-clinical</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-announces-encouraging-efficacy-and-safety-profile-ongoing-phase-1-clinical</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients</description>
</item>
<item>
<title>Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-host-virtual-event-discussing-updated-phase-1a-and-phase-1b</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-host-virtual-event-discussing-updated-phase-1a-and-phase-1b</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>The virtual event will take place on Monday, December 1, 2025, at 4:30 PM ET SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a</description>
</item>
<item>
<title>Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-third-quarter-2025-financial-results-and-business</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-third-quarter-2025-financial-results-and-business</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 $989.0 million in cash, cash equivalents,</description>
</item>
<item>
<title>Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-second-quarter-2025-financial-results-and-business</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-second-quarter-2025-financial-results-and-business</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment</description>
</item>
<item>
<title>Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-clinical-milestone-200500170</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-announces-clinical-milestone-200500170</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, August 05, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced the dosing of the first patient in its TRACTr collaboration with Merck, known as MSD outside of the United States and Canada</description>
</item>
<item>
<title>Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-highlights-pipeline-progress-and-best-class-potential-novel</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-highlights-pipeline-progress-and-best-class-potential-novel</guid>
<pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
<description>PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and</description>
</item>
<item>
<title>Janux Therapeutics to Host Virtual R&D Day on July 24, 2025</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-host-virtual-rd-day-july-24-2025-2025-07-17</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-host-virtual-rd-day-july-24-2025-2025-07-17</guid>
<pubDate>Thu, 17 Jul 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel</description>
</item>
<item>
<title>Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-appoints-janeen-doyle-chief-corporate-and-business-development</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-appoints-janeen-doyle-chief-corporate-and-business-development</guid>
<pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
<description>Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems SAN</description>
</item>
<item>
<title>Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-first-quarter-2025-financial-results-and-business</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-first-quarter-2025-financial-results-and-business</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase</description>
</item>
<item>
<title>Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-initiates-phase-1b-expansion-studies-janx007-patients-prostate</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-initiates-phase-1b-expansion-studies-janx007-patients-prostate</guid>
<pubDate>Mon, 05 May 2025 04:00:00 GMT</pubDate>
<description>Phase 1b expansion study initiated in taxane-naïve mCRPC patients Updated data from Phase 1a dose escalation support initiation of Phase 1b dose expansion</description>
</item>
<item>
<title>Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and</guid>
<pubDate>Thu, 27 Feb 2025 05:00:00 GMT</pubDate>
<description>Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC Enrollment ongoing for JANX007 and JANX008 Update on JANX007 and</description>
</item>
<item>
<title>Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer</title>
<link>https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-promotes-zachariah-mciver-do-phd-chief-medical-officer-2025-01-24</link>
<guid isPermaLink="true">https://6ix.com/company/janux-therapeutics-inc/news/janux-therapeutics-promotes-zachariah-mciver-do-phd-chief-medical-officer-2025-01-24</guid>
<pubDate>Fri, 24 Jan 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel</description>
</item>
</channel>
</rss>